Genotype 2

  1. G2 naïve NON-CIRRHOTIC
    1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks à 99-100% SVR12 (ASTRAL-1 and 2)
    2. SOF 400MG QD + DCV 60 MG QD for 12 weeks –> >90% SVR12 ((Wyles, NEJM 2015); (Sulkowski, NEJM 2014a)

 

  1. G2 naïve COMPENSATED CIRRHOTIC
    1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks –> 99-100% SVR12 (ASTRAL-1 and 2)
    2. SOF 400MG QD + DCV 60 MG QD for 24 weeks –> ?% SVR12 ((Wyles, NEJM 2015); (Sulkowski, NEJM 2014a)

 

  1. G2 prior treatment failure NON-CIRRHOTIC
    1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks –> 99% SVR12 (ASTRAL- 2)
    2. SOF 400MG QD + DCV 60 MG QD for 12 weeks –> ?% SVR12 ((Wyles, NEJM 2015); (Sulkowski, NEJM 2014a) [who are not eligible to receive RBV]

 

  1. G2 prior treatment failure COMPENSATED CIRRHOTIC
    1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily for 12 weeks –> 99% SVR12 (ASTRAL- 2)
    2. SOF 400MG QD + DCV 60 MG QD for 24 weeks –> ?% SVR12 ((Wyles, NEJM 2015); (Sulkowski, NEJM 2014a)

 

  1. G4 DECOMPENSATED CIRRHOTIC
    1. Epclusa [VEL/SOF daily fixed dose combination] 1 tab daily +/- RBV WBD for 12 weeks –> 100% SVR12 [ASTRAL-4]

 

 

Clinic Visits and Labs                                                                                                                  

  1. Initiation of Therapy
  2. Week 2 – CBC, CMP
  3. Week 4 – CBC, CMP, HCV RNA PCR quantitative
  4. Week 8 – CBC, CMP
  5. Week 12 – CBC, CMP, HCV RNA PCR quantitative
  6. Week 4 Post Therapy – CBC, CMP, HCV RNA PCR quantitative
  7. Week 12 Post Therapy – CBC, CMP, HCV RNA PCR quantitative – SVR12

**If finish at Week 16 or 24 – CBC, CMP, HCV RNA PCR quantitative

SOF = Sofosbuvir [Solvaldi] – NS5B nucleotide analog polymerase inhibitor

DCV = Daclatasvir [60 mg daily] [DAKLINZA] – NS5A inhibitor

VEL = Velpatasvir [100 mg daily] – NS5A inhibitor

 

 

 

Share on FacebookShare on Google+Share on LinkedInTweet about this on TwitterEmail this to someonePrint this page